Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Granting a Marketing Authorisation for Zanubrutinib for the Treatment of Waldenström’s Macroglobulinaemia

It is indicated in patients who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy
21 Oct 2021
Anticancer agents & Biologic therapy;  Haematologic malignancies

On 16 September 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product zanubrutinib (Brukinsa), intended for the treatment of Waldenström’s macroglobulinaemia.

The applicant for this medicinal product is BeiGene Ireland Ltd.

Brukinsa will be available as 80 mg hard capsules. The active substance of Brukinsa is zanubrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor (ATC code: L01EL03) which blocks the activity of BTK inactivating the pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion.

The benefits of Brukinsa are a clinically meaningful rate of very good partial response and/or complete response.

The most common side effects are neutropenia, thrombocytopenia, upper respiratory tract infection, haemorrhage/haematoma, rash, bruising, anaemia, musculoskeletal pain, diarrhoea, pneumonia and cough.

The full indication is:

Brukinsa as monotherapy is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy.

Brukinsa should be prescribed by physicians experienced in the use of anticancer medicinal products.

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion.

This product was designated as an orphan medicine during its development. EMA will now review the information available to date to determine if the orphan designation can be maintained.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings